It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Prompt treatment is critical to slow the progression of wet macular degeneration (wet AMD), a condition that can lead to severe vision loss.

Over the past few decades, treatment options for wet AMD have advanced and treatment is now more effective1. Treatment with an anti-VEGF is now the standard of care for wet macular degeneration1


Pre-1980: No Treatment

Rapid and progressive vision loss.

Early 1990s: Thermal Laser

Thermal laser treatments had high rates of vision loss and recurring disease, and were not an option for all patients2.

Early 2000s: Photodynamic Therapy

Slowed the progression of vision loss, but vision did not improve in a majority of patients3.

2000-present: Anti-VEGF treatment 

Anti-VEGF treatments have reduced the incidence of legal blindness and severe vision loss in wet macular degeneration patients4,5.

For more information about anti-VEGF treatment, click here.


1Gehrs KM, Anderson DH, Johnson LV, and Hageman GS. Age-related macular degeneration—emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38:450-471.​

2Kent C. Rev Ophthalmol 2009. Available at: ​

3Brown DM, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study. Ophthalmology 2009;116:57-65.​

4Freund KB, et al. An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother. 2013;14:1017-1028.​

5Holz FG, et al. Recent developments in the treatment of age-related macular degeneration. J Clin Invest. 2014;124:1430-1438.

Curated Tags